This shift is mediated by the induction of RIPK3, a necroptosis regulator, contributing to liver injury and fibrosis.[38] As a modulator of lipid metabolism and liver injury ATF3 has emerged as a potential therapeutic target for managing liver diseases like MASH, MAFLD, and T2D. This evidence concerns the gene ATF3 and liver disorder.